Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Biochemical abnormalities among patients referred for celiac disease antibody blood testing in a primary health care setting

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Reduced levels of pulmonary surfactant in COVID-19 ARDS

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Chronic inflammation markers and cytokine-specific autoantibodies in Danish blood donors with restless legs syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Stefania Kalogera
  • Yi He
  • Anne-Christine Bay-Jensen
  • Thorbjørn Gantzel
  • Shu Sun
  • Tina Manon-Jensen
  • Morten Asser Karsdal
  • Christian S Thudium
Vis graf over relationer

Osteoarthritis (OA) and rheumatoid arthritis (RA) are serious and painful diseases. Protease-activated receptor 2 (PAR2) is involved in the pathology of both OA and RA including roles in synovial hyperplasia, cartilage destruction, osteophyogenesis and pain. PAR2 is activated via cleavage of its N-terminus by serine proteases. In this study a competitive ELISA assay was developed targeting the 36-amino acid peptide that is cleaved and released after PAR2 activation (PRO-PAR2). Technical assay parameters including antibody specificity, intra- and inter-assay variation (CV%), linearity, accuracy, analyte stability and interference were evaluated. PRO-PAR2 release was confirmed after in vitro cleavage of PAR2 recombinant protein and treatment of human synovial explants with matriptase. Serum levels of 22 healthy individuals, 23 OA patients and 15 RA patients as well as a subset of RA patients treated with tocilizumab were evaluated. The PRO-PAR2 antibody was specific for the neo-epitope and intra-inter assay CV% were 6.4% and 5.8% respectively. In vitro cleavage and matriptase treated explants showed increased PRO-PAR2 levels compared to controls. In serum, PRO-PAR2 levels were increased in RA patients and decreased in RA patients treated with tocilizumab. In conclusion, PRO-PAR2 may be a potential biomarker for monitoring RA disease and pharmacodynamics of treatment.

TidsskriftScientific Reports
Udgave nummer1
Sider (fra-til)24285
StatusUdgivet - 20 dec. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 69983607